Clinical design and competition issues By Kathryn Calkins
& Ilan Zipkin

On the heels of a negative review by FDA's Peripheral and Central Nervous System Drugs Advisory Committee, Cephalon Inc. faces the decision whether to conduct an additional trial of Myotrophin IGF-1 to confirm the positive results of its North American trial in amyotrophic lateral sclerosis.